Precipio Inc., Speciality Cancer Diagnostics Company, on Monday announced that Mr Carl Iberger, CFO of the company for the past five years, is resigning from his designation, effective as of 21 March 2022.
Mr Iberger wishes to spend more time with his family, and therefore he has decided to step down from his role as CFO. Besides his resignation, the company also announced the name of the interim CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis, has been promoted to Interim Chief Financial Officer of the company effective immediately.
Mr Gage has been working in the company since 2017. He has worked closely with Mr Iberger and managed the company’s accounting functions and public filings. Matt has over 30 years of experience in company finance and 25 years within traded companies. He is the ideal candidate for this role due to his rich experience and knowledge of the company’s business, finance and internal controls & procedures.
Regarding the resignation, Carl Iberger stated that ━ “It has been an incredible six years, and I am proud of being a part of such an amazing team. It was an honour to work closely with Ilan Danieli, CEO of Precipio, and the board. I have no doubt that Matt will do exceptionally well as Interim CFO. At the age of 69, I am looking forward to the next chapter of my life as I want to spend more time with my family.”
“We are so pleased to have Matt as Interim CFO of the company. His knowledge of the process and procedure will allow him to transition into his new role,” stated Ilan Danieli. “Carl has been a pillar of stability, guidance and support to the company. In his presence, I could able to focus business growth, knowing that the company’s financial matters were in extremely capable hands.” His managerial, organizational and interpersonal skills were outstanding. He has been a mentor to me and a friend. Carl’s impact on the company and the people around is invaluable, and his departure is a bittersweet moment for all of us, he added.